Related Experiment Video

Updated: Feb 6, 2026

Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT
07:07

Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT

Published on: May 2, 2017

14.4K

Hepatic Involvement of IgG4-Related Disease Presenting as Multiple Hypermetabolic Masses on FDG PET/CT

Qingqing Pan, Ying Wang, Yaping Luo

    Clinical Nuclear Medicine
    |August 15, 2018
    PubMed

    Insights

    Multifocal hepatic masses on PET/CT may indicate IgG4-related disease, a condition mimicking cancer. Early diagnosis and treatment with prednisone effectively reduced lesions in this case.

    Area of Science:

    • Immunology
    • Oncology
    • Radiology

    Background:

    • Multiple hepatic masses on imaging can suggest metastatic disease.
    • IgG4-related disease (IgG4-RD) is a fibroinflammatory condition that can affect multiple organs.
    • Differentiating IgG4-RD from malignancy is crucial for appropriate treatment.

    More Related Videos

    Functional Imaging of Brown Fat in Mice with 18F-FDG micro-PET/CT10:53

    Functional Imaging of Brown Fat in Mice with 18F-FDG micro-PET/CT

    Published on: November 23, 2012

    19.8K
    Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates10:04

    Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

    Published on: September 5, 2017

    19.3K

    Related Concept Videos

    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

    Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
    281
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
    247
    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

    In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
    206
    Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

    Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

    In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
    234
    Hepatic Portal System01:21

    Hepatic Portal System

    The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
    At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
    6.0K
    Atomic Mass01:52

    Atomic Mass

    Atoms — and the protons, neutrons, and electrons that compose them — are extremely small. For example, a carbon atom weighs less than 2 × 10−23 g. When describing the properties of tiny objects such as atoms, we use appropriately small units of measure, such as the atomic mass unit (amu). The amu was originally defined based on hydrogen, the lightest element, then later in terms of oxygen. Since 1961, it has been defined with regard to the most abundant isotope of carbon, atoms of which...
    70.3K